Loading...
XLON
PRM
Market cap9mUSD
Dec 05, Last price  
2.40GBP
1D
-14.29%
1Q
-30.84%
Jan 2017
-56.36%
Name

Proteome Sciences PLC

Chart & Performance

D1W1MN
XLON:PRM chart
P/E
P/S
1.45
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-81.00%
Revenues
5m
-2.80%
16,00068,000266,000849,0001,306,0009,980,0001,021,0001,152,96724,870,000,00019,008,000,00019,641,000,00019,818,000,00018,927,000,00019,668,000,00019,730,000,00016,945,000,00022,593,000,00023,736,000,0005,028,0004,887,000
Net income
-3m
L+39.42%
-6,897,000-5,638,000-5,252,000-4,624,000-4,010,0004,563,000-3,957,000-4,253,594540,000,000-453,000,000-626,000,0001,562,000,000587,000,0001,597,000,0002,461,000,0001,526,000,0006,205,000,0005,023,000,000-2,443,000-3,406,000
CFO
-826k
L+71.73%
-4,769,000-3,606,000-4,093,000-4,122,000-2,972,0004,003,000-5,166,000-3,353,367-11,550,000,000-6,267,000,00046,633,000,000-31,695,000,00055,473,000,000-14,780,000,000-21,451,000,000-7,744,000,00010,522,000,0003,882,000,000-481,000-826,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.
IPO date
Oct 03, 1995
Employees
27
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT